Enliven: Challenges in Cancer Detection and Therapy

Author Invitation Submit Manuscript
Journal Sections
Cancer Genetic Pathways
AnalyzingGenetic pathways in cancer.
Cell Cycle Control and Cancer
Cell cycle regulation and controlling factors in cancer.
Apoptosis and Cancer
Cancer factor causing programmed cell death.
Cancer and Stem Cells
Stem cells role in cancer therapy and treatment.
Cancer Therapeutics
Therapeutic drugs in cancer treatment.
Cancer Research
Research on studies, discoveries, drugs, and innovationsin cancer treatment and prevention.
Cancer Drug Discovery and Applications
Developing drugs with drug discovery in cancer treatment.
Cancer Genomics and Proteomics
Cancer genomics is the study of structure, function, evaluation, and mapping of cancer genomes.
Tumor Immunology
Study of interactions between the immune system and cancer cells.
Cancer Epidemiology and Etiology
Cancer Epidemiologyis the study of the factors affecting cancer. Cancer Etiology is the study of the cause, set of causes, or manner of causation of cancer.
Cancer and Biostatistics
Statistical analysis of cancer datasets.
Cancer Prevention
Preventive measures and methods to eradicate cancer.
Cancer and Pharmaceutics
Drug formulations and advancements in cancer treatment.
Cancer Pathology
Study of cancer affected cells and detailed observation of cancerous cells
Oncology Cancer and Radiation Studies
Radiation methods for cancer treatment.
Cancer Cell Biology
Detailed study of cancerous cells
Cancer Associated Pathways
Metabolic and other pathways in causing cancer.
Cancer Clinical Research
Clinical studies and research analysis in cancer.
Cancer Alternative Therapies
Study and analysis of all associated therapies in cancer treatment.
Cancer Types
Detailing the types and cancer forms
Cancer Chemotherapy
Cancer treatment using drugs to destruct malignant cells and tissues
Journal Features
  • All submissions will undergo vigorous peer review process.
  • High quality review process.
  • Permanent published archives.
  • Author loyal benefits.
  • Reviewer credits.
  • Visible specified citations.
  • Open access - Maximum dissemination.
  • Un-interrupted author communication.
  • Standard author guidelines.
  • Minimal publication charges with convenient and safe modes of transfer.
Enliven: Challenges in Cancer Detection and Therapy

Enliven: Challenges in Cancer Detection and Therapy is an Open access, peer reviewed international journal and it aims to publish different types of articles on emerging developments and supports current and upcoming research in the field of cancer. This journal also allows articles on tumor studies, oncology and radiation.

This journal will support the budding scientists, scholars, academicians, researchers, and students by providing Open access platform for publishing their work.

This journal will follow the peer review policies and will bode Open access in having quality research output.

Enliven: Challenges in Cancer Detection and Therapy invites articles from authors and we assure authors that articles received will be processed with the best policies and will disseminate the articles to the right field.

Enliven: Challenges in Cancer Detection and Therapy journal is interested to publish high quality original research and reviews in all areas of cancer and related fields.

This journal invites articles from all areas like molecular, subcellular, cellular, organ, clinical and translational studies of cancer.

This journal supports to exchange ideas, concepts and findings, discoveries, and current developments in cancer, oncology research, and related fields. This journal provides the Open Access forum to quick and effective dissemination of new research in cancer for better world.

Official Media Partners:

3rd International Cancer Conference and Expo welcomes you as our guest to the City of Baltimore, USA during June 05-07, 2019. iCancer USA 2019 aims in "Driving Innovative Cancer Science Towards Precision Medicine".

This conference provides a forum for exchange of ideas and authoritative views by eminent personalities in this exciting field, by bringing together Cancer Science, Drug Development, Nanotechnology in Cancer Treatment, Robotic Surgery, Therapies, Oncology, Clinical trials, Cancer imaging, Medical radiation, Cancer detection, Control and Prevention research professionals; Academicians, Doctors, Study sponsors, Related Associations & Societies; Executives from Bio-Engineering, Diagnosis Tools, Medical devices and Pharmaceutical industries around the globe.

World Hematology 2019 is comprised of many interactive scientific sessions on different types of Blood disorders and Cancers as well as various diagnostic and therapeutic advancements in this field. It is an initiative to unite the diverse research and business communities working in this field under one roof to explore every single aspect of Oncology and Hematology.

Breast Cancer2019  welcomes attendees, presenters, and exhibitors from all over the world to Dublin, Ireland. We are delighted to invite you all to attend and register for the "2nd World Congress on Breast Cancer " which is going to be held during August 19-20, 2019 at Dublin, Ireland.



Recent Articles
Subscribe News Letter Recommend Peers / Library
Recent News

The TGF-beta family signaling is specificity, versatility and control.

  • Free trade of TGF- beta family signaling edge to develpmental anomalies and disease, where as appriciate TGF- beta Signaling committ to cancer and fibrosis.

In bone repair the nanocomposite scaffold seeded withmesenchymal stem cell.

  • the bone tissue engineering remained problematic in mechanical equity of bone tissue scaffolds is one of the most important aspects.

Genistein assure H9c2 cardiomyocytes across chemical Hypoxia-induced injury alond inhibition of Apoptosis.

  • The main aim of cardioprotective effect of gen across chemical hypoxia- induced injury.

The equivalent of BRCA2 variation on bounded prostate cancer.

  • Permissive the tumaor to evade androgen deprivation therapy,BRCA2-mutant tumours can harbour a subpopulation of cancer cell that can accept castration de novo.

In Dyserythropoietic disorders and Physiological Erythropoiesis the pleiotropic effects of GATA1 and KLF1.

  • The evoluation of later bearing sequencing has futher identification of pathological alteration affect TFs underlying hematological defects.